| Aclidinium: in chronic obstructive pulmonary disease. | |
| | |
MedLine Citation:
|
PMID: 23046206 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aclidinium, an inhaled, long-acting antimuscarinic agent, has been developed as a twice-daily maintenance treatment for chronic obstructive pulmonary disease (COPD). Treatment with the approved dosage of aclidinium (400 μg twice daily) statistically significantly improved bronchodilation, disease-specific health status, dyspnoea, night-time COPD symptoms and use of rescue medication compared with placebo in pivotal studies of 12 (ACCORD COPD I) or 24 (ATTAIN) weeks duration in patients with moderate to severe COPD. The improvements in bronchodilation, health status and dyspnoea were clinically meaningful compared with placebo after 24 weeks of treatment in ATTAIN; generally similar results were seen after 12 weeks of treatment in both trials. Aclidinium also statistically significantly reduced the incidence of COPD exacerbations compared with placebo in these studies (albeit neither trial was designed to assess exacerbation frequency). Inhaled aclidinium has a low systemic bioavailability; the approved dosage was generally well tolerated in clinical trials of up to 52 weeks duration. Aclidinium had an adverse event profile that was similar to that of placebo and characterized by low incidences of major adverse cardiovascular events and potential anticholinergic adverse events. |
| | |
Authors:
|
James E Frampton |
Related Documents
:
|
18536066 - Effects of warm-supplementing kidney yang (wsky) capsule added on risperidone on cognit... 9892856 - Amisulpride versus amineptine and placebo for the treatment of dysthymia. 12590356 - Changes in cognitive functioning with risperidone and olanzapine treatment: a large-sca... 15705006 - Effects of behavioral therapy on weight loss in overweight and obese patients with schi... 23244366 - Sudden gains in cognitive therapy and interpersonal therapy for social anxiety disorder. 19724996 - insight into illness: an overview of the concept focusing on schizophrenia |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Drugs Volume: 72 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1999-2011 Citation Subset: IM |
Affiliation:
|
Adis, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Interactions of DPPC with semitelechelic poly(glycerol methacrylate)s with perfluoroalkyl endgroups.
Next Document: Multivariate mixed linear model analysis of longitudinal data: an information-rich statistical techn...